Oral prednisolone for 4 days does not increase exercise tolerance in men with COPD

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Oral prednisolone for 4 days does not increase exercise tolerance in men with COPD. / Karlsson, SL; Backer, V; Godtfredsen, Nina Skavlan.

In: Chronic Respiratory Disease, Vol. 15, No. 2, 2018, p. 220-222.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Karlsson, SL, Backer, V & Godtfredsen, NS 2018, 'Oral prednisolone for 4 days does not increase exercise tolerance in men with COPD', Chronic Respiratory Disease, vol. 15, no. 2, pp. 220-222. https://doi.org/10.1177/1479972317721929

APA

Karlsson, SL., Backer, V., & Godtfredsen, N. S. (2018). Oral prednisolone for 4 days does not increase exercise tolerance in men with COPD. Chronic Respiratory Disease, 15(2), 220-222. https://doi.org/10.1177/1479972317721929

Vancouver

Karlsson SL, Backer V, Godtfredsen NS. Oral prednisolone for 4 days does not increase exercise tolerance in men with COPD. Chronic Respiratory Disease. 2018;15(2):220-222. https://doi.org/10.1177/1479972317721929

Author

Karlsson, SL ; Backer, V ; Godtfredsen, Nina Skavlan. / Oral prednisolone for 4 days does not increase exercise tolerance in men with COPD. In: Chronic Respiratory Disease. 2018 ; Vol. 15, No. 2. pp. 220-222.

Bibtex

@article{793f03b8a60b47de91e100e03e2774f2,
title = "Oral prednisolone for 4 days does not increase exercise tolerance in men with COPD",
abstract = "One of the primary objectives in management of chronic obstructive pulmonary disease (COPD) is preventing decrease in lung function and reducing the annual number of acute exacerbations of COPD (AECOPD). An oral course of systemic corticosteroids is a commonly used treatment in AECOPD. We hypothesize that this treatment also increases exercise performance and decreases muscle fatigue. In a randomized double-blinded, parallel, placebo-controlled trial, we investigated 14 men (8 on prednisolone 37.5 mg vs. 6 on placebo) with severe and very severe COPD. For 5 consecutive days, the patients performed a submaximal endurance test measuring time to exhaustion (TTE, primary endpoint), spirometry, maximal inspiratory and expiratory pressure and maximal isometric contraction of the quadriceps femoris muscle (maximum voluntary contraction (MVC)). At visits 2, 3 and 4, a fatigue protocol was carried out after 40 minutes of cycling at 40% of maximal effort. No differences between groups were found for TTE, lung function or maximal inspiratory or expiratory pressure, however, patients on prednisolone showed significant increased MVC: median 5.15 [3.35; 9.15] against placebo: -2 [-5.57; 3.95] ( p = 0.03). This finding indicates an impact of corticosteroids on muscle groups being exposed to submaximal endurance.",
author = "SL Karlsson and V Backer and Godtfredsen, {Nina Skavlan}",
year = "2018",
doi = "10.1177/1479972317721929",
language = "English",
volume = "15",
pages = "220--222",
journal = "Chronic Respiratory Disease",
issn = "1479-9723",
publisher = "SAGE Publications",
number = "2",

}

RIS

TY - JOUR

T1 - Oral prednisolone for 4 days does not increase exercise tolerance in men with COPD

AU - Karlsson, SL

AU - Backer, V

AU - Godtfredsen, Nina Skavlan

PY - 2018

Y1 - 2018

N2 - One of the primary objectives in management of chronic obstructive pulmonary disease (COPD) is preventing decrease in lung function and reducing the annual number of acute exacerbations of COPD (AECOPD). An oral course of systemic corticosteroids is a commonly used treatment in AECOPD. We hypothesize that this treatment also increases exercise performance and decreases muscle fatigue. In a randomized double-blinded, parallel, placebo-controlled trial, we investigated 14 men (8 on prednisolone 37.5 mg vs. 6 on placebo) with severe and very severe COPD. For 5 consecutive days, the patients performed a submaximal endurance test measuring time to exhaustion (TTE, primary endpoint), spirometry, maximal inspiratory and expiratory pressure and maximal isometric contraction of the quadriceps femoris muscle (maximum voluntary contraction (MVC)). At visits 2, 3 and 4, a fatigue protocol was carried out after 40 minutes of cycling at 40% of maximal effort. No differences between groups were found for TTE, lung function or maximal inspiratory or expiratory pressure, however, patients on prednisolone showed significant increased MVC: median 5.15 [3.35; 9.15] against placebo: -2 [-5.57; 3.95] ( p = 0.03). This finding indicates an impact of corticosteroids on muscle groups being exposed to submaximal endurance.

AB - One of the primary objectives in management of chronic obstructive pulmonary disease (COPD) is preventing decrease in lung function and reducing the annual number of acute exacerbations of COPD (AECOPD). An oral course of systemic corticosteroids is a commonly used treatment in AECOPD. We hypothesize that this treatment also increases exercise performance and decreases muscle fatigue. In a randomized double-blinded, parallel, placebo-controlled trial, we investigated 14 men (8 on prednisolone 37.5 mg vs. 6 on placebo) with severe and very severe COPD. For 5 consecutive days, the patients performed a submaximal endurance test measuring time to exhaustion (TTE, primary endpoint), spirometry, maximal inspiratory and expiratory pressure and maximal isometric contraction of the quadriceps femoris muscle (maximum voluntary contraction (MVC)). At visits 2, 3 and 4, a fatigue protocol was carried out after 40 minutes of cycling at 40% of maximal effort. No differences between groups were found for TTE, lung function or maximal inspiratory or expiratory pressure, however, patients on prednisolone showed significant increased MVC: median 5.15 [3.35; 9.15] against placebo: -2 [-5.57; 3.95] ( p = 0.03). This finding indicates an impact of corticosteroids on muscle groups being exposed to submaximal endurance.

U2 - 10.1177/1479972317721929

DO - 10.1177/1479972317721929

M3 - Journal article

C2 - 28718320

VL - 15

SP - 220

EP - 222

JO - Chronic Respiratory Disease

JF - Chronic Respiratory Disease

SN - 1479-9723

IS - 2

ER -

ID: 217614783